Advanced Angiosarcoma (AS) is a rare and aggressive form of cancer that forms in the lining of blood vessels and…
Browsing: Sarcoma
In this enlightening interview, esteemed Oncologist Gary Schwartz, MD discusses the promising development and potential of Cabozantinib plus Nivolumab as…
ASCO (American Society of Clinical Oncology) [2022] Sarcomas Cancer In-Depth Slides: MOASC Â Dr. Warren Chow’s MOASC Presentation on ASCO…
Kilian E. Salerno, MD, vice chair of the guideline task force and a radiation oncologist at the National Cancer Institute…
Kilian E. Salerno, MD, vice chair of the guideline task force and a radiation oncologist at the National Cancer Institute…
Erik A. Williams, MD of the Foundation Medicine, Inc. discusses CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor…
Rafael G Amado, MD, Adaptimmune, LLC, Hopes T-cell Therapies Will Lead to Approval Difficult to treat solid tumors with adoptive…
Jon Eckard, PhD, TYME Inc., shares Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects at…
Rafael G Amado, MD, Adaptimmune, LLC, explains MRCLS Responded to Active Therapy Treatment Harvested T-Cells transduced with antiviral vector at…
Rafael G Amado, MD, Adaptimmune, LLC, explains Infusion of T-Lymphocytes with T-Cell Receptor MRCLS could be sensitive to therapy at…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, shares Myxoid Round Cell Liposarcoma Expresses NY-ESO-1 T-Cell therapy targeting NY-ESO-1…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, talks about Creating a number of followup studies Testing checkpoint Inhibitors,…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Lots of Patients with Refractory Sarcomas Considering Off-Label Checkpoint Inhibitor
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Undifferentiated Pleomorphic Sarcoma Can respond to checkpoint blockade like pembrolizumab…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Sarcoma Subtypes React to Different Immunotherapy Have inflammatory tumor-immune micro-environments…